Pramlintide
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
AstraZeneca · Phase 2 · Terminated · Enrollment 213
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Group A | n/r | n/r | n/r | n/r |
| Group B | n/r | n/r | n/r | n/r |
| Placebo | n/r | n/r | n/r | n/r |
| Pramlintide + Metreleptin | n/r | n/r | n/r | n/r |
Not shown
- Group A: endpoint not reported
- Group B: endpoint not reported
- Placebo: endpoint not reported
- Pramlintide + Metreleptin: endpoint not reported